Mantle cell lymphoma is a type of cancer that starts in the cells of the lymph system. The lymph system is part of the immune system and helps to fight off infections. Mantle cell lymphoma is a rare type of cancer, accounting for about 6 percent of all lymphomas.
Mantle cell lymphoma usually occurs in people over the age of 60. The average age at diagnosis is 71. The disease is more common in men than in women.
Mantle cell lymphoma is typically treated with chemotherapy and radiation. However, these treatments are not always successful.
Now, researchers from the University of Colorado have found a new way to target mantle cell lymphoma. The new method uses a targeted therapy called Deckorator.
Deckorator is a type of monoclonal antibody. Monoclonal antibodies are man-made proteins that can bind to specific targets. In this case, Deckorator binds to a protein called CD20, which is found on the surface of B cells.
B cells are a type of white blood cell. They play a role in the immune response.
The researchers found that Deckorator was able to kill mantle cell lymphoma cells in the lab. They also found that the treatment was well-tolerated in mice.
The next step is to test Deckorator in humans. The researchers hope that this new treatment will be more effective than current treatments for mantle cell lymphoma.
A new study has found that a molecule known as CCL17 could be a potential target for treating mantle cell lymphoma (MCL).
MCL is a type of blood cancer that is typically difficult to treat. The average lifespan of someone with MCL is only about five years from the time of diagnosis.
There are currently only two FDA-approved treatments for MCL, and both have significant side effects.
The new study, published in the journal Nature Medicine, suggests that CCL17 could be a new target for treating MCL.
CCL17 is a chemokine that is overexpressed in MCL cells. Chemokines are proteins that help to regulate the body’s immune response.
The researchers found that CCL17 was necessary for the survival of MCL cells. When they targeted CCL17 with a new antibody, the MCL cells died.
The researchers believe that this discovery could lead to the development of new and improved treatments for MCL that are less toxic and more effective.
This is an exciting discovery that provides new hope for those with MCL.
